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In Parkinson’s disease (PD) degeneration of mesocortical dopaminergic projections may determine cognitive and behavioral
symptoms. Choice reaction time task is related to attention, working memory, and goal-directed behavior. Such paradigm involves
frontal cortical circuits receiving mesocortical dopamine which are affected early in PD. The aim of this study is to characterize
the role of dopamine on the cognitive processes that precede movement in a reaction time paradigm in PD. We enrolled 16 newly
diagnosed and untreated patients with PD without cognitive impairment or depression and 10 control subjects with essential tremor.
They performed multiple-choice reaction time task with the right upper limb and brain 18 F-DOPA PET/CT scan. A significant
inverse correlation was highlighted between average reaction time and 18 F-DOPA uptake in the left lateral orbitofrontal cortex.
No correlations were found between reaction time and PD disease severity or between reaction time and 18 F-DOPA uptake in
controls. Our study shows that in PD, but not in controls, reaction time is inversely related to the levels of dopamine in the left
lateral orbitofrontal cortex. This novel finding underlines the role of dopamine in the lateral orbitofrontal cortex in the early stages
of PD, supporting a relation between the compensatory cortical dopamine and movement preparation.

1. Introduction
Early manifestations of Parkinson’s disease (PD) may include
cognitive and affective abnormalities involving multiple
domains such as attention, working memory, visuospatial
abilities [1], apathy and depression [2]. Most of these clinical
features have been related to a frontal dysexecutive syndrome
whose neurobiological substrate can be referred to as an
unbalanced mesocortical dopaminergic activity [3].
The neurodegenerative process in PD involves nigrostriatal dopaminergic neurons but also those originating from

the ventral-tegmental area and projecting to the frontal cortex
through the mesocortical pathway [4]. While the nigrostriatal
network is mainly responsible for the motor aspects of PD, the
mesocortical network is essentially involved in cognitive and
behavioral symptoms [5]. Both in human and animal models,
the role of dopamine in motivation, reward, impulsivity,
attention, working memory, and goal-directed behavior has
been highlighted [6–10]. The orbitofrontal cortex is involved
in goal-directed behavior and has a pivotal role within the
mesocortical pathway. In fact, orbitofrontal cortex receives
dopaminergic input from the ventral-tegmental area and
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modulates the dopaminergic output of the mesocortical pathway [9]. Choice reaction time tasks involve frontal cortical
circuits controlling attention, working memory, and goaldirected behavior; these resources, which are also related
to learning abilities, seem to be decreased in PD [11]. The
aim of this study is to characterize the role of dopamine
(as measured by 18 F-DOPA PET) during motor preparation,
investigated using a multiple-choice reaction time paradigm
in early untreated PD patients.

2. Methods
2.1. Subjects. Subjects were sixteen patients affected by idiopathic PD consistent with established guidelines (age 67 ± 7,
mean ± SD), 3 females, H&Y stages 1-2, and UPDRS-III 16±5.
They were all right-handed (as assessed by the Edinburgh
Handedness Inventory), newly diagnosed, and drug naı̈ve. All
of them showed asymmetric presentation with the left side
more affected in 11 patients, the right side in the remaining
5. Ten patients with a clinical diagnosis of essential tremor
were enrolled as controls (age 68 ± 10, 6 females). None
had significant cognitive impairment, as confirmed by a neuropsychological assessment including the Mini-Mental State
Examination (MMSE) where all patients scored more than
26 (Table 1). The presence of significant depressive symptoms
was also excluded by the 15-item Geriatric Depression Scale
(GDS) where all patients scored less than 6.
Although healthy subjects would have been more suitable
as control subjects, it is known that patients with essential
tremor have a normal 18 F-DOPA PET [12]. It must be said that
there are heavy ethical and regulatory difficulties in studying
healthy controls with radioactive compounds. Moreover, in
the clinical setting the differential diagnosis is often between
PD and essential tremor, rather than healthy subjects, and
thus essential tremor represents the usual group PD patients
are compared with.
The present study has been carried out in accordance with
the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; a
written informed consent was obtained from all participants.
The study was approved by the local Ethics Committee.
2.2. Motor Task. All subjects were naı̈ve to the task and
therefore performed a short training session, leading to a
smooth performance. It must be underlined that the training
phase was short enough so that the subjects still needed
to exert significant attentional effort and did not reach
an automatic habitual control during the following motor
task. The experimental setup has been described in detail
in previous works [13]; briefly, subjects moved a cursor
on a digitizing tablet with their right (dominant) hand.
Movements were out and back from a central starting point
to one of eight radial targets displayed on a computer screen.
The targets’ distance from the central point was 4.8 cm.
One of eight circular empty targets turned black on the
screen in synchrony with a tone at fixed intervals of 1.5 s
in unpredictable order. Subjects were asked to reach for the
target making out and back movements “as soon as possible”
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Table 1: Patients demographic data.
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1
2
3
4
5
6
7
8
9
10

Group
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
ET
ET
ET
ET
ET
ET
ET
ET
ET
ET

Sex
M
M
M
M
F
M
M
F
M
M
M
M
M
F
M
M
M
F
M
F
M
F
F
F
M
F

Age
65
65
64
73
74
66
65
76
68
74
60
68
47
74
65
62
73
68
84
79
77
57
54
60
67
63

MMSE
29
28
30
29
29
29
30
29
27
29
28
28
30
30
30
28
30
27
29
29
29
29
30
29
30
29

UPDRS-III
22
21
9
14
12
11
10
23
19
23
14
12
15
18
15
16

MAH
R
R
R
L
R
L
L
R
R
R
R
L
L
R
R
R

MAH: more affected hemisphere.

and “as fast as possible,” thus minimizing reaction time and
movement duration. Instructions were also to make the out
and back movements without corrections, reversing sharply
inside each target circle. When the subjects reached the target
within 1.5 s, before the next one turning black, the target circle
turned gray, indicating a successful hit. Subjects received a
feedback about their performance at the end of each block.
The described experimental paradigm can be considered a
multiple-choice reaction time task since the subjects deploy
attention toward eight targets and then reach for the one
that turns black. All subjects performed 160 consecutive
reaching movements into two blocks of 80 movements each.
We measured reaction time during reaching movements as
the time between the target appearance and the movement
onset; for each subject we computed the average reaction time
across the 160 movements (Figure 1).
The Motor Task Manager software (ETT, Electronic Technology Team, Genoa, Italy) controlled the protocol execution,
path acquisition, and offline analysis of the data.
2.3. Image Protocol
2.3.1. 18 F-DOPA PET/CT. The patients and control subjects
fasted for at least 4 hours before the start of 18 F-DOPA
PET/CT acquisition. On arrival subjects were given oral
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Velocity

1: target presentation

3
2: outgoing movement

3: return movement

Reaction time
Time

1: target
presentation

2: outgoing
movement onset

3: return
movement onset

Figure 1: Motor task. (1) One of eight targets turns black (target
presentation); then (2) the patient moves the cursor toward the
target as soon as possible (outgoing movement) and (3) returns to
the centre right after reaching the target (return movement). The
reaction time is the time required to start the movement after target
presentation.

carbidopa (2.5 mg/kg), and one hour later, they received
185 MBq of 18 F-DOPA intravenously. 18 F-DOPA (IASOdopa,
IASON Labormedizin Gesmbh & Co.Kg, Graz-Seiersberg,
Austria) was produced as previously described [14]. Brain
scans were acquired 90 minutes after injection [15]. Data were
obtained using a dedicated PET/CT system (Discovery STE,
GE Medical Systems, Milwaukee, WI, USA) using the 3D
mode with a scanning time of 30 minutes. A nondiagnostic,
low-dose CT scan (120 kV, 80 mA, 0.6 s per rotation) was used
for attenuation correction.
Static (single frame) acquisition was preferred to dynamic
one because it is more practical in a clinical setting. As
a matter of fact, 18 F-DOPA brain kinetics is exceedingly
complex. Different modeling approaches have been proposed
and still research and discussion are open on these issues [16].
Meanwhile, static acquisition with normalization of uptake
values on a reference region (cerebellum or occipital lobe)
has been validated as a simpler and suitable approach for
both research and clinical purposes [15, 17] and has been
increasingly used in studies of Parkinsonian patients [18, 19].
Moreover, normalized uptake values on reference regions
tightly correlate with kinetic parameters [15] and have similar
diagnostic accuracy in PD as kinetic parameters [15, 17,
18]. Also, in PD similar diagnostic accuracy for occipitalnormalized 18 F-DOPA uptake as 123 I-FP-CIT SPECT has
been demonstrated [19–21]. The PET scan was performed
within one month from the motor task.
2.3.2. MRI. All patients and control subjects underwent
brain Magnetic Resonance Imaging (MRI) by means of a
1.5 T superconductive system (Signa HDxt, GE Healthcare,
Milwaukee, WI) to acquire a sagittal T1-FFE sequence with
the following parameters: TR 8.7 ms, TE 4.1 ms, flip angle

8∘ , FOV 256 mm, matrix 256 × 256, 150 sagittal slices (1.0mm thick), and voxel size 0.98 × 0.98 × 1.6. White matter
hyperintensities were graded according to the Wahlund’s
scale [22] and no patient scored more than 1 in each brain
region.
2.4. Images Processing. All preprocessing and statistical analysis steps were performed using SPM8 package (Wellcome
Department of Cognitive Neurology, London, UK) implemented in Matlab 6.5 (Mathworks, Natick, Massachusetts,
USA).
Since it was shown that the use of a tracer-unmatched
PET template to normalize brain scans may generate inconsistent results [23] and since SPM default brain PET template
is H2 15 O template, a fully MRI-based normalization was
applied [24]. Each 18 F-DOPA PET scan was first coregistered
to the pertinent MRI scan (six parameters, rigid body
transformation) using the coregistration algorithm available
in the SPM8 package. Each MR image was then spatially
normalized to the SPM8 T1-MRI template using an affine plus
nonlinear transformation, and the resulting deformation field
was applied to the coregistered 18 F-DOPA PET scan. The
spatially normalized PET images were finally smoothed with
a 6-mm isotropic Gaussian filter to blur individual anatomic
variations and to increase the signal-to-noise ratio.
The voxel-based approach was chosen because it allows
good spatial normalization of individual images to a
stereotactic-normalized template, thus reducing the intersubject variability for anatomic topography, that is, allowing
comparison of the same region among different subjects.
This ability avoids systematic errors in ROI positioning or
erroneous identification of striatal or extrastriatal regions
in PET images with a low signal-to-noise ratio. Second,
SPM tool interrogates all brain regions in an operatorindependent way allowing estimating both striatal subregions
and extrastriatal regions [25, 26].
2.5. Statistics. In order to fully explore correlation between
dopaminergic (dys)function and average reaction time, both
native images and images “flipped” with the more affected
hemisphere (MAH) on the left side were independently submitted to the analysis. According to the clinical asymmetry
in body impairment, since the right hemisphere was more
affected in eleven PD patients and the left one in five, we
explored also the hypothesis that possible correlation clusters
derived from the relatively higher or lower involvement of
the two hemispheres. Thus, after performing the first analyses
we also repeated analyses after “flipping” the hemispheres
so as to have the more affected hemisphere always on the
right and the less affected one always on the left side of
the brain. The MAH was defined as the contralateral one
to the side of the body with prevalence of motor symptoms
as assessed by the referring clinician. “Multiple Regression
Analysis” was chosen between the possible designs available
in “Basic Models” function of SPM8. This option allows the
voxel-wise evaluation of the correlation between a variable of
interest (average reaction time) and PET-assessed dopaminergic activity as well as nuisance effect (age, education, and
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Table 2: Results of correlation analysis between mean reaction time (RT) and dopaminergic activity as assessed through 18 F-DOPA PET in
de novo Parkinson’s disease patients.
Analysis

RT

Cluster level
Cluster extent Corrected 𝑝 value Cortical region Maximum 𝑍 score
L-frontal
6.02
L-frontal
5.59
126
0.05
L-temporal
4.83

Peak level
Talairach coordinates
−42
40
−19
−46
30
−17
−48
20
−20

Cortical region
BA
Middle frontal gyrus
11
Inferior frontal gyrus
47
Superior temporal gyrus 38

Uncorrected 𝑝 < 0.001 at peak level and 𝑝 < 0.05, false discovery rate corrected at cluster level, were accepted as statistically significant. In the “cluster level”
section on the left, for each cluster found to be statistically significant are reported the number of voxels, the corrected 𝑝 value, and the cortical region where the
cluster is found. In the “peak level” section on the right, for each significant cluster are reported the peak coordinates and 𝑍 score, the corresponding cortical
region and Brodmann area (BA).

UPDRS-III were included as nuisance variables to account
for possible influence of these variables on both reaction time
and PET data) both in PD and in control groups (UPDRS-III
in PD only). Global calculation was performed on cerebellar
counts previously obtained by means of MarsBaR, a regionof-interest analysis subtool of SPM [27]. SPM-T maps were
displayed using an uncorrected 𝑝 < 0.001 at peak level.
This more liberal choice was adopted to avoid type II
errors attributable to overconservative thresholds [28]. Given
the exploratory nature of this analysis and considering the
relatively low sensitivity of PET without repeated measures,
higher thresholds could lead to false-negative results in PET
studies. Clusters of correlations were regarded as significant
if they survived at 𝑝 < 0.05 threshold, FDR-corrected at
cluster level. Only significant clusters containing at least 50
voxels were taken into consideration. Correction of SPM
coordinates to match the Talairach coordinates was achieved
by the subroutine implemented by Matthew Brett [29].
Brodmann areas (BA) were then identified at a range of 0 to
3 mm from the corrected Talairach coordinates of the SPM
output isocenters, after importing the corrected coordinates,
by Talairach client [30].
A factorial ANOVA was performed to compare reaction
time between PD and controls, while the correlation between
reaction time and UPDRS-III was computed with a linear
regression analysis.

3. Results
All subjects successfully learned to perform the task, and
their out and back movements were smooth with overlapping
trajectories, returning to the center before the appearance of
the next target. The average reaction time in the PD group was
302±50 ms, while in the control group it was 341±85 ms, with
no significant difference between the two groups (𝐹[1, 24] =
2.2, 𝑝 = 0.2). The reaction time was unrelated to the UPDRSIII scale.
DOPA uptake was significantly lower in PD than in control group in bilateral striatum, mainly in the more affected
hemisphere. A significant inverse correlation was highlighted
between average reaction time and PET-assessed dopaminergic activity in the left middle and inferior frontal gyri (BA
11 and 47), corresponding to the left lateral orbitofrontal
cortex, and, to a lesser extent, in the left superior temporal
gyrus (BA 38) as shown in Figure 2. The same correlation lost

significance when images were flipped with the MAH on the
left side. No significant correlation was found in any other
brain regions. See Table 2 for further details and 𝑍 scores.
In the control group, no correlation could be found between
reaction time and PET-assessed dopaminergic activity in any
brain area.

4. Discussion
This study demonstrates that the reaction time during a
choice reaction time paradigm is inversely correlated to the
dopaminergic activity in the left lateral orbitofrontal cortex
in untreated patients in the early stages of PD but not in
patients with essential tremor. Specifically, a higher reaction
time corresponded to lower dopaminergic activity in the
left lateral orbitofrontal cortex and vice versa. One of the
most characteristic motor features of PD is the increased
time in movement onset, as reflected experimentally with
an increased reaction time especially in choice reaction time
tasks [31]. Such slowness in movement preparation is less
evident in the early stages of the disease, although slight
between-subjects variability in reaction time may still be able
to disclose early disruption of the brain network underlying
movement preparation in PD [11]. Our PD patients were
in the early stages of the disease and did not show a
significant increase in reaction time if compared with those
with essential tremor. This finding is not unexpected since
reaction time can be increased also in essential tremor, where
the altered functioning of brain areas such as the cerebellum
could determine an increased reaction time involving neural
mechanisms different from those of PD [32].
Reaction time encompasses the time required to detect
and direct attention toward the highlighted target and to plan
the appropriate response. Thus reaction time appears to be an
ideal parameter to provide a temporal measure required by
these cognitive processes. Since all the tested subjects were
naı̈ve to the task and underwent only a short preliminary
training, their performance was still significantly linked to
attentional resources. Recent studies show that attention
is impaired in PD, particularly cognitive flexibility [33].
Attentional resources depend on the prefrontal dopaminergic
function and are involved in movement preparation as they
are needed to focus on the target. Indeed, dopamine enhances
the stability of task-relevant representations by promoting
distractor resistance [34, 35]. In addition, in patients with PD,
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Figure 2: Correlation between 18 F-DOPA uptake and reaction
time. The upper panel shows whole brain voxel-wise correlation
analysis depicting (superimposed to a brain rendering) the sites
of significant inverse correlation between reaction time and PETassessed dopaminergic activity. The cluster includes areas pertaining
to the middle and inferior frontal as well as the superior temporal
gyri in the left hemisphere. The lower panel shows the plot as
automatically generated by SPM expressing the correlation between
the two variables after transformation of the native values around 0.

reaction time in choice reaction time tasks may improve after
levodopa administration [36, 37], although this improvement
is not paralleled by a similar improvement of the cognitive
network underlying declarative learning [36].
Dopaminergic projections to the frontal cortex are mediated by the mesocortical pathway. In particular orbitofrontal
cortex, which seems to guide behavior based on expected
reward, not only receives mesocortical dopaminergic inputs,
but also may modulate dopaminergic output of the ventraltegmental area, where most of the mesocortical neurons
originate [9]. Recent animal studies underline the importance
of dopamine in high level cognitive functioning, working
memory, risk-based decision making, and attention [8] but

also for the process of attending external stimuli and for associative learning [6]. These evidences underline the existence
of a shared functional background between the orbitofrontal
cortex and the cognitive processes underlying reaction time
as evaluated in our motor task.
Despite encouraging results in animal models, the role
of dopamine in human cognition is still poorly understood.
Dopaminergic therapy in particular, despite being usually
effective on motor symptoms, may produce supranormal
dopaminergic transmission in limbic and associative cortical
networks, determining a variable interplay between failure
and adaptation of different brain circuitry [38]. Since PD
patients in this study were all drug naı̈ve, the role of endogenous dopamine has not been affected by dopaminergic drugs.
An explanation for the inverse correlation between dopaminergic activity in the lateral orbitofrontal cortex and reaction
time could reside in a compensatory supranormal dopaminergic activity mostly in those patients showing a lower
reaction time. Conversely, the lack of correlation between
reaction time and UPDRS-III, a clinical scale that estimates
motor impairment in PD patients, favors the hypothesis
that reaction time is not necessarily related to overall motor
impairment [11]. Even in naı̈ve PD, the degree of impairment
of the dopaminergic system is very variable among patients;
similarly the compensatory mesocortical activity is likely to
be higher in PD patients with lower levels of endogenous
dopamine and vice versa. The absent correlation between
dopaminergic activity in the lateral orbitofrontal cortex and
reaction in the control group is probably a consequence of
the integrity of the dopaminergic system in patients with
essential tremor, determining much more uniform dopamine
levels and reduced variability among subjects.
The possible role of reward, which is mediated by dopaminergic pathways in the orbitofrontal cortex, has been
demonstrated in both human [7, 9] and animal studies [6, 8,
10]. Even if the motor task we used has not been specifically
designed to study reward, it was somewhat challenging
because of the short time interval between targets and the
positive feedback of the target turning gray after a successful
hit. Such features could have modulated reaction time in
relation to the individual expected reward, determining a
shorter (better) reaction time in those PD patients where
dopamine levels in the lateral orbitofrontal cortex were
higher, probably because of more preserved and upregulated
mesocortical projections [9].
We found that reaction time correlated with dopaminergic activity of the left lateral orbitofrontal cortex but not
with the right one. Importantly, such correlation was lost if
the brain hemispheres were flipped in order to match the
more affected side of PD patients. This could mean that the
correlation involves the left cortex independently on the body
side where the motor features are more evident. Lateralization
of dopaminergic activity has already been shown in the
striatum of PD patients as measured by SPECT with 123 Ib-CIT [39] and 18 F-DOPA [3] while considering frontal
cognitive tasks. It is likely that the reaction time correlates
that we have studied are actually localized in the left lateral
orbitofrontal cortex; however we cannot exclude that such
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lateralization is related to the use of the right arm while
performing the motor task. Having tested the patients only
with the right arm is of course a limitation of this study;
investigating the motor performance bilaterally may be useful
in future studies to better understand motor and cognitive
effect of an asymmetric dopaminergic brain activity.
Although 18 F-DOPA uptake is mainly related to dopaminergic transmission, it is not a specific ligand for dopamine
neurons since its uptake is related to the aromatic amino
acid decarboxylase (AADC) enzyme, present also in other
monoaminergic neurons. It is therefore possible that at least
part of the correlation we found could be related also to
noradrenergic or serotoninergic activity in the same brain
area [4]. Even if PD is mainly a dopamine-related disorder
and therefore dopamine is more likely responsible for the
present findings, the role of other monoamines is intriguing.
Noradrenaline in particular has a role in vigilance and attention and, like dopamine, is reduced in PD brains [40]. On the
other hand frontal serotonin is involved in response inhibition, which is modulated by serotonin reuptake inhibitors in
PD [41].
In conclusion the present study contributes to the understanding of the neural mechanisms underlying reaction time
and the related cognitive processes such as attention, stimulus
perception, movement preparation, and the possible role of
reward. Our results help to understand the role of left lateral
orbitofrontal cortex in patients with Parkinson’s disease.
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